Müller P, Simon B
Innere Abteilung, Krankenhaus Salem, Heidelberg.
Fortschr Med. 1996 Dec 20;114(35-36):497-9.
For the eradication of Helicobacter pylori in H.p.-positive patients with peptic ulcer, preference is presently being given worldwide to the modified triple therapy-comprising an acid suppressant and two antibiotics. This relatively new form of treatment is highly effective, relatively well tolerated, patient-friendly (5 to 6 tablets daily), and inexpensive. In 12 studies involving more than 600 patients, the new proton pump inhibitor, lansoprazole, has proved to be an effective component of this eradication regimen. In combination with clarithromycin and metronidazole or amoxicillin and clarithromycin, consistently high eradication rates of more than 85% are obtained, with treatment of only seven days duration. Since in terms of clinical efficacy 30 mg lansoprazole daily presumably correspond to 40 mg omeprazole daily, the new proton pump inhibitor represents a more economic alternative for H.p. eradication.
对于幽门螺杆菌(H.p.)阳性消化性溃疡患者的幽门螺杆菌根除治疗,目前全球范围内更倾向于采用改良三联疗法,即包含一种抑酸剂和两种抗生素。这种相对较新的治疗形式疗效显著、耐受性相对良好、对患者友好(每日服用5至6片药)且成本低廉。在涉及600多名患者的12项研究中,新型质子泵抑制剂兰索拉唑已被证明是这种根除方案的有效成分。与克拉霉素和甲硝唑或阿莫西林和克拉霉素联合使用时,仅需治疗7天,根除率始终高于85%。由于就临床疗效而言,每日30毫克兰索拉唑可能相当于每日40毫克奥美拉唑,这种新型质子泵抑制剂是根除幽门螺杆菌的更经济选择。